OncoSpherix is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of small molecule therapeutics that inhibit the function of the transcription factors hypoxia-inducible factors 1 and 2 (HIF-1 and HIF-2). The patent portfolio includes novel composition of matter and use of lead and follow-on compounds. The technology was licensed from Emory and Ga State Universities. HIFs are activated in regions of tumor hypoxia (low oxygen), a situation that occurs when tumor cells outgrow their blood supplies, a situation that occurs in nearly all solid tumors. Activated HIFs enable tumor cells to survive and spread from these regions. Efficacy of lead compounds has been shown both as single agents and as part of combination therapy in multiple types of cancer, including pancreatic, breast, glioblastoma, lung, and ocular melanoma. OncoSpherix?s HIF inhibitors can be safely and effectively combined with different types of therapies, often leading to synergy. The clinical lead is approximately 18 months from launch of phase 1 testing for advanced cancer.